David Gate retweeted
New paper from the Colonna lab! cMAF is a key regulator of BAM identity and drives communication with brain arteries via IGF1. We show that this cMAF-dependent program in BAMs supports cerebrovascular function in mice and is protective against AD.
cell.com/cell/fulltext/S0092…
Really amazing collaboration with such an excellent team of researchers. My lab was fortunate to play a part in this fantastic work.
The transcription factor MAF is known from human genetics to be important in Alzheimer’s disease, but its precise function within the brain has been unclear.
Our latest, out today in @CellCellPress, dissects the role of MAF in brain macrophages. 1/
cell.com/cell/fulltext/S0092…
Excited to share our latest work on ALS neuroimmunology, published today in @NatureNeuro rdcu.be/fiFM0
David Gate retweeted
Genetically altered astrocytes that express chimeric antigen receptors offer a promising immunotherapy system capable of clearing accumulations of amyloid-β in the brains of mice—a hallmark pathological feature of #AlzheimersDisease, according to a new study in Science.
📄: scim.ag/3NjPIfP
#SciencePerspective: scim.ag/4rgI1oL
David Gate retweeted
Congrats @DGateLab on having one of the Top 3 Episodes of Breakthroughs Podcast in 2025! If you haven't listened you can do so and learn more here; news.feinberg.northwestern.e…
David Gate retweeted
Key to research success: ambition in vision, but pragmatism in execution. You must be guided by a long-term, ambitious goal that addresses a fundamental problem, rather than chasing incremental gains on established benchmarks. Yet, your progress should be grounded by tractable short-term metrics/tasks that force you to constantly make contact with reality.
David Gate retweeted
We are proud to announce a collaboration with @ARC_Neuro at Northwestern University Feinberg School of Medicine to harness AI for rapid discovery and innovation in Alzheimer’s disease research. Using Lens, the Center and Tempus teams will work together to uncover genomic patterns that have the potential to advance the understanding of Alzheimer’s disease, investigate the gene and cell types affected, enable the development of new therapeutics, and accelerate the creation of novel clinical applications.
Learn more: tempus.co/43EIlVJ
David Gate retweeted
I am excited to present our new study out in @NatureMedicine where we discover a novel synaptic protein biomarker to predict if and when someone will get Alzheimer’s disease dementia. Part 2/3 from my PhD work in the @wysscoray lab. 🧵1/12
Full study 🔗: nature.com/articles/s41591-0…
The Gate lab is fortunate to have such a talented scientist like @TerryRSuk joining us soon. Check out his impressive work!
We’re happy to share that our labs first #ALS and #FTD study “A stress-dependent TDP-43 SUMOylation program preserves neuronal function” is now online @MolNeuro!
doi.org/10.1186/s13024-025-0…
It’s quite an experience to have some of your favorite labs like @TheColonnaLab and @Haass_Lab comment on your lab’s research. Great reporting by Alzforum! alzforum.org/news/research-n…
This Northwestern Breakthroughs podcast nicely encapsulates our study. The host does a great job leading the discussion for the lay audience to digest our work. I hope this allows people to better understand the results and impact of this study. youtu.be/bZrdwGQ_Ok0
This video describes the findings from our recent study conducted at @ARC_Neuro. In the video, lead author @LynnOlst and I discuss the findings and their implications for Alzheimer’s disease. youtu.be/pnRzktJRWAo
David Gate retweeted
アルツハイマー病の治療は脳自身のクリーンアップクルーにあるかもしれません nipponese.news/%e3%82%a2%e3%…
David Gate retweeted
Excited to share our latest @NatureMedicine study from our new center @ARC_Neuro! 🧠✨ Using spatial transcriptomics & scRNA-seq, we uncover how Aβ-targeting immunotherapies shape microglial responses in AD patient brains.
A thread with our key findings is below! 🧵(1/15)
David Gate retweeted
Spatial transcriptomics reveals distinct microglial mechanisms driving amyloid-β clearance in both passive and actively immunized #Alzheimer’s disease patients @NUFeinbergMed
nature.com/articles/s41591-0…














